1. 'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma—A multicentre, retrospective study.
- Author
-
Wilson, Matthew R., Haynes, Euan, Parsons, Katrina, Hopkins, David, Robertson, Elizabeth, Ferguson, Graeme, Quinn, Daire, Murray, Jim, Osborne, Wendy, Leach, Mike, and McKay, Pam
- Subjects
HODGKIN'S disease ,OLDER patients ,CANCER chemotherapy ,BLEOMYCIN ,PREDNISOLONE - Abstract
Summary: Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone), whereby bleomycin and etoposide were removed and cyclophosphamide dose was reduced, for older patients with co‐morbidities. Here we present data from the first 41 patients treated with 'ACOPP' across 3 centres, demonstrating that it can be delivered, with a favourable toxicity profile (TRM 2%) and promising efficacy (2‐year PFS and OS, 73% (95% CI: 52–94) and 93% (95% CI: 80–100) respectively). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF